2012 CRE Toolkit - Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE)
Part 2: Regional CRE Prevention
Appendix A: Previous and Current Clinical and Laboratory Standards Institute Interpretive Criteria for Carbapenems and Enterobacteriaceae
Agent | Previous Breakpoints (M100-S19) MIC (μg/mL) | Current Breakpoints (M100-S22) MIC (μg/mL) | ||||
---|---|---|---|---|---|---|
Susceptible | Intermediate | Resistant | Susceptible | Intermediate | Resistant | |
Doripenem | - | - | - | ≤1 | 2 | ≤4 |
Ertapenem | ≤2 | 4 | ≥8 | ≤0.5 | 1 | ≥2 |
Imipenem | ≤4 | 8 | ≥16 | ≤1 | 2 | ≥4 |
Meropenem | ≤4 | 8 | ≥16 | ≤1 | 2 | ≥4 |
Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing; Twenty Second Informational Supplement (January 2012). CLSI document M100-S22. Wayne, Pennsylvania, 2012.
Get email updates
To receive email updates about this page, enter your email address:
Contact Us:
- Centers for Disease Control and Prevention
1600 Clifton Rd
Atlanta, GA 30333 - 800-CDC-INFO
(800-232-4636)
TTY: (888) 232-6348 - New Hours of Operation
8am-8pm ET/Monday-Friday
Closed Holidays - cdcinfo@cdc.gov